Cytotoxic t-cell epitope peptide and use thereof

A cytotoxic, epitope peptide technology, applied in the field of anti-cancer agents, passive immunotherapy agents, cancer vaccines and anti-cancer agents, CTL peptides, can solve the problem of unknown CKAP4 antigenicity

Inactive Publication Date: 2018-02-16
MEDICAL & BIOLOGICAL LAB CO LTD
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0041] As mentioned above, CKAP4 is considered to be highly expressed in various cancers, but the antigenicity of CKAP4 in cancer cells is not known

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cytotoxic t-cell epitope peptide and use thereof
  • Cytotoxic t-cell epitope peptide and use thereof
  • Cytotoxic t-cell epitope peptide and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0365] [Selection of EBV-specific CTL epitope candidate peptides]

[0366]EBV is classified into type 1 and type 2 according to differences in expressed proteins and the like. Most of the infections and lurking in humans are type 1, and type 2 infections mainly AG876 are rare in Asia (Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen2. Proc Natl Acad Sci US A. 1984 Dec;81(23):7632-6). However, there are also reports of EBV co-infection cases in the same individual, and there are also reports of ethnic and regional diversity of EBV infection strains (Apolloni A, Sculley TB. Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes. Virology. 1994 Aug 1; 202(2): 978-81, Correa RM, Fellner MD, Alonio LV, Durand K, Teyssie AR, Picconi MA. Epstein-barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. J Med V...

Embodiment 2

[0515] [Prediction of CKAP4-specific HLA-A*24:02-restricted epitope peptides]

[0516] CKAP4 is a type II membrane protein with a full length of 602 amino acids, and no isoform has been reported. The selection of CKAP4-specific CTL epitope candidate peptides of the present invention was carried out on HLA-A*24:02 which is retained by about 60% of Japanese. Specifically, it was carried out referring to a plurality of software published on the Internet that can search for CTL epitope candidate peptides consisting of 8 to 12 amino acids having a binding motif to HLA-A*24:02. As a result, 10 CTL epitope candidate peptides consisting of 9 to 10 amino acids having a binding motif of HLA-A*24:02 were selected from the amino acid sequence of CKAP4, and the peptides were synthesized. Synthetic CTL epitope candidate peptides are shown below.

[0517] Synthetic HLA-A*24:02-binding CKAP4-specific CTL epitope candidate peptide

[0518] Arg Leu Gly Arg Ala Leu Asn Phe Leu Phe (Serial Num...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides a cytotoxic T-cell (cytotoxic T lymphocyte, abbreviated hereinafter as CTL) epitope peptide specific to the Epstein-Barr virus (described hereinafter as EBV), a vaccinefor treating or preventing EBV infection or EBV-positive cancer using this peptide, a passive immunotherapeutic agent for EBV, and a method for assaying CTL specific to EBV. The present invention alsoprovides an HLA-A*24:02-restricted epitope peptide comprising an IYTEVRELV sequence (SEQ ID NO: 43) from a cytoskeleton-associated protein (cytoskeleton-associated protein 4: CKAP4 hereinafter, alsoknown as: CLIMP-63, ERGIC-63, P63). The peptide-specific cytotoxic T-cells (CTL hereinafter) can attack malignant tumor cells that express a high level of CKAP4.

Description

technical field [0001] The present invention relates to a cytotoxic T cell (cytotoxic T lymphocyte, hereinafter referred to as CTL) epitope peptide specific for Epstein-Barr virus (hereinafter referred to as EBV), and treatment or prevention of EBV infection using the peptide A vaccine for the virus-positive cancer, a passive immunotherapy agent against EBV, and a method for quantifying CTL specific for EBV. In addition, the present invention also relates to peptides capable of inducing CTLs targeting cancer cells. In addition, the present invention also relates to a cancer vaccine and an anticancer agent containing the aforementioned peptide. The present invention also relates to uses of the aforementioned peptides for inducing CTLs targeting cancer cells, obtained CTLs, and anticancer agents containing the aforementioned CTLs. Background technique [0002] In 1964, Epstein and Barr discovered a new herpes virus from cultured cells from Burkitt's lymphoma tissue and named...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K35/15A61K35/17A61K39/245A61P35/00C07K16/18C12N15/00C12Q1/02
CPCA61K35/15A61K35/17A61K39/245C07K7/08C07K16/18C12N15/00C12Q1/02
Inventor 李栋梁大鹰弘纪中野一绘田路真悟
Owner MEDICAL & BIOLOGICAL LAB CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap